Abstract: Transdermal estrogen/progestin adsorption dosage units have been developed which comprise a backing layer, an adjoining polymer layer is an adhesive layer in which at least minimum effective dose of an estrogen is dissolved or microdispersed. Adhered to the polymer layer is an adhesive layer in which is dissolved and/or microdispersed at least minimum doses of progestin. Presently preferred is use of the natural estrogen, 17-beta-estradiol, or ethinyl estradiol or combinations thereof and of the progestin. The units have biologically acceptable adhesive and polymer layers. The adhesive layer can have dispersed one or more skin permeation enhancing agents. A separating layer can optionally be used in making the dosage units, which separate the adhesive and polymer layers, which permits estrogen transmission from the polymer layer during treatment. Dosage units are provided which transdermally deliver at least minimum daily doses of the estrogen and progestin for multiple days, such as for one week.

Abstract: A dosage form is disclosed comprising a first composition comprising two different polyethylene oxide osmopolymers for delivering a drug at a controlled rate over time.

Abstract: Penetration of various drugs through living membranes is improved by their use in transdermal compositions containing certain penetration-enhancing systems. A new delivery device is also described.

Abstract: A method of producing an alkaline earth or alkaline earth metal phosphide-based hydrogen phosphide generating pest control agent by completely coating even surfaced bodies of the alkaline earth or alkaline earth metal phosphide with a moisture-permeable coating which delays the generation of the hydrogen phosphide therefrom for a desired period of several hours up to one month and which is formed from moisture-pervious, solid, organic materials.

Abstract: Sustained-release oral drug-dosage forms that release drug in solution at a rate controlled by the solubility of the drug are described. The dosage form comprises a tablet or capsule which comprises a plurality of particles of a dispersion of a limited solubility drug in a hydrophilic, water-swellable, crosslinked polymer that maintains its physical integrity over the dosing lifetime but thereafter rapidly dissolves. Once ingested, the particles swell to promote gastric retention and permit the gastric fluid to penetrate the particles, dissolve drug and leach it from the particles, assuring that drug reaches the stomach in the solution state which is less injurious to the stomach than solid-state drug.

Abstract: Film coated pharmaceutical preparations, which are prepared by overlaying to the outer surface of pharmaceutical preparations, a coating layer comprising at least one member selected from the group consisting of methyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, carboxymethylethyl cellulose and cellulose acetate phthalate, are irradiated with light including ultraviolet rays. Whereby film coated pharmaceutical preparations, the coating layer surface of which are excellent in whiteness, are prepared. Moreover, as a content of a white pigment in corporated into the coating layer of such preparations may be reduced, the stability of such preparations can be enhanced without impairing the strength of the coating layer.

Abstract: A dosage form is disclosed comprising a coat that surrounds a drug. The coat comprises a subcoat and an overcoat thermally annealed to provide a single unit coat around the drug.

Abstract: A solid state, resilient laminated composite for administering a drug transdermally consisting of a multiplicity of spaced structural laminas of a resilient elastomer, one of which forms the top of the composite, a viscoelastic hydrophobic polymer lamina containing propylene glycol monolaurate interposed between each structural lamina and a pressure-sensitive adhesive lamina that provides the basal surface of the composite and consists of a blend of a pressure-sensitive adhesive, drug and propylene glycol monolaurate.

Abstract: An improved pharmaceutical preparation uses tromethamine and dibasic potassium phosphate or calcium carbonate to enhance stability.

Abstract: Rate controlled transdermal nicotine delivery systems are disclosed which utilize an in-line adhesive to maintain the systems on the skin. The initial equilibrated concentration of nicotine in the nicotine reservoir and the adhesive is below saturation, preferably at a thermodynamic activity no greater than 0.50, and the reservoir comprises the nicotine dissolved in a material with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of nicotine in the reservoir is sufficient to prevent the activity of the nicotine in the reservoir from decreasing by more than about 75% and preferably no more than about 25% during the predetermined period of administration; and the thickness of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and, preferably at least 75% of the initial equilibrated nicotine loading is in the reservoir layer.

Abstract: A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which wll be co-extensively coadministered with the sensitizing agent.

Abstract: A biocompatible, film-forming delivery system for the delivery of pharmaceutical or therapeutic actives to a desired topical site of a subject, the system including:an active salt compound, wherein the active salt compound is at least a partial salt of(1) a carboxylic acid moiety-containing, biocompatible, film-forming polymer with(2) at least one active selected from the group consisting of pharmaceutical actives, therapeutic actives and a combination thereof, wherein the at least one active is capable of complexing with at least one carboxylic acid moiety of the polymer to form the active salt compound, andwherein the active salt compound forms an active salt compound film on the topical site and the active salt compound disassociates into the polymer and the at least one active while the delivery system is in contact with the topical site such that the polymer remains thereon as a polymer film and the at least one active is delivered to the topical site in an absorbable form.

Abstract: Encapsulated drugs are employed for introduction into the chambers of the eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Abstract: The instant invention is directed to a method for enhancing the lowering of plasma cholesterol level in a subject in need thereof which comprises the time-controlled administration of a nontoxic therapeutically effective amount of an HMG-CoA reductase inhibitor to said subject which surprisingly affords an equivalent or improved reduction of plasma cholesterol levels while significantly reducing the amount of HMG-CoA reductase inhibitor circulating in the bloodstream of the subject as compared to the same parameters when the oral administration of a conventional rapid release dosage form is utilized.

Abstract: A composition, particularly an oral composition, for improving the smoothness of the skin, wherein GLA or DGLA or both as such or in the form of physiologically acceptable and equivalent derivatives are brought into administrable form with a carrier or diluent.

Abstract: Fluorocarbon polymer powder particles, e.g. particulate PTFE, are included, as a solid lubricant, in the binder applied to dental floss or tape.

Abstract: The invention relates to a covered, solid retard form which in the case of oral administration remains in the stomach during periodic emptying and ensures continuous release. This dosage form contains the following components:(a) at least one component that expands on contact with body fluid and that contains a physiologically active substance or a combination of such substances,(b) at least one permeable hydrophilic membrane which surrounds component (a) and which is expansible at the site of use, and optionally(c) a covering which surrounds components (a) and membrance (b) and which disintegrates without delay under the action of a body fluid at the site of use.

Abstract: A delivery device is disclosed for delivering a beneficial agent to an animal. The device comprises a wall housing an internal space, a beneficial agent in the space, expandable means in the space for causing the beneficial agent to be delivered from the device and means in the space for shielding the beneficial agent from fluid.

Abstract: A composition comprising a flexible backing for a transdermal drug preparation with a water vapor transmission rate about equal to or in excess of that of ethylene vinyl alcohol copolymer, namely equal to or in excess of, at one mil thickness, of about 2 to 4 grams and more preferably in excess of 6 grams per 24 hours per 100 square inches at 40.degree. C. and 90% relative humidity and an oxygen transmission rate equal to or less than ethylene vinyl alcohol copolymer, namely at one mil thickness equal to or less than about 0.01 to 0.1 cubic centimeters per 100 square inches measured over 24 hours at 1 atmospheric pressure, 20.degree. C. and 65% relative humidity.

Abstract: The present invention relates to a therapeutic system with systemic action for peroral administration, having a compartment for active ingredients, which system contains in that compartment sparingly soluble active ingredients, swelling agents and, optionally, water-soluble substances for producing an osmotic pressure.